RGX-314 Gene Therapy Study for Wet AMD: This study is testing a new treatment called ABBV-RGX-314, designed for people with a condition called neovascular age-related macular degeneration (wet AMD). Wet AMD is a serious eye disease that causes vision loss because of new, leaky blood vessels in the eye. Current treatments require frequent eye injections, which can be burdensome. ABBV-RGX-314 aims to offer a one-time gene therapy option to help improve vision without the need for regular injections.

The study involves around 660 participants and compares two doses of RGX-314 with another treatment called aflibercept. The main goal is to see how well RGX-314 can improve vision compared to aflibercept. People aged 50 to 89 who have been previously treated for wet AMD may be eligible to participate.

• The study lasts about 2 years and involves several visits to the clinic.
• Participants will receive compensation for their time and travel.
• There are risks involved, including possible eye problems, and participants must meet certain health criteria.